Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study

A Bewley, D M Burrage, S J Ersser, M Hansen, C Ward, A Bewley, D M Burrage, S J Ersser, M Hansen, C Ward

Abstract

Background: Psoriasis has a serious impact on patients' lives. However, adherence to medications is often poor, potentially compounding the burden of disease. Identifying patients who need support with psychosocial problems, or issues with adherence, can be complex.

Objectives: We aimed to develop statements that could assist the consultation process, identifying the relative importance of factors related to effective management of psoriasis for patients.

Methods: A two-stage study design was used to comprehensively identify, and assess validity of, statements describing psoriasis impact and management issues. Both components were conducted in Canada, France, Germany, Italy, Spain, the United Kingdom and the United States. Findings from patient observation and interviews were analysed for pattern strength, and were then used to inform the development of statements that were quantitatively assessed using a survey. The association of drivers towards agreement with 'my psoriasis dictates how I lead my life' was assessed using anova.

Results: Fifty-six patients participated in the qualitative component, and 1,884 patients using prescription medications completed the survey. Two thematic categories were identified; disappointment with treatments, and confusion regarding psoriasis associated with a lack of direction. When assessed quantitatively, key statements associated with a strong burden of psoriasis on patients' lives were related to isolation, social stigma, visible symptoms, impact on activities and feelings of hopelessness. A mixture of patient-, doctor- and treatment-related factors were among the most common reasons for non-adherence.

Conclusion: Questioning using the statements most associated with psychosocial impact and non-adherence could help identify patients with additional support needs, and assist in overcoming adherence issues.

© 2013 The Authors Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of the European Academy of Dermatology and Venereology.

Figures

Figure 1
Figure 1
Factors most strongly associated with ‘my psoriasis dictates how I lead my life’*. *all P < 0.03; Adjusted R-squared 0.61; †question was posed negatively, which gave a negative coefficient.
Figure 2
Figure 2
Reasons for non-adherence given by patients using topical prescription medication(s). *n = 799. Statements agreed with by >10% patients reporting non-adherence are shown.

References

    1. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139.
    1. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol. 2010;24:885–892.
    1. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155:729–736.
    1. Young M. The psychological and social burdens of psoriasis. Dermatol Nurs. 2005;17:15–19.
    1. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
    1. Hrehorow E, Salomon J, Matusiak L, et al. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2011;92:67–72.
    1. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61–67.
    1. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses’ health study II. Arch Intern Med. 2007;167:1670–1675.
    1. Finzi A, Colombo D, Caputo A, et al. Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study. J Eur Acad Dermatol Venereol. 2007;21:1161–1169.
    1. Colombo D, Caputo A, Finzi A, et al. Evolution of and risk factors for psychological distress in patients with psoriasis: the PSYCHAE study. Int J Immunopathol Pharmacol. 2010;23:297–306.
    1. Ersser SJ, Surridge H, Wiles A. What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract. 2002;8:367–376.
    1. Horne R. One to be taken as directed: reflections on non-adherence (non-compliance) J. Soc. Adm. Pharm. 1993;10:150–156.
    1. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9–14.
    1. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222:363–374.
    1. Fortune DG, Richards HL, Main CJ, et al. What patients with psoriasis believe about their condition. J Am Acad Dermatol. 1998;39:196–201.
    1. Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151:895–897.
    1. Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147:1285–1294.
    1. Pope C, Ziebland S, Mays N. Analysing qualitative data. BMJ. 2000;320:114–116.
    1. Heydendael VM, de Borgie CA, Spuls PI, et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9:131–135.
    1. Evers AW, Lu Y, Duller P, et al. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152:1275–1281.
    1. Schneider G, Heuft G, Hockmann J. Determinants of social anxiety and social avoidance in psoriasis outpatients. J Eur Acad Dermatol Venereol. 2013;27:383–386.
    1. Uttjek M, Dufaker M, Nygren L, et al. Psoriasis care consumption and expectations from a gender perspective in a psoriasis population in northern Sweden. Acta Derm Venereol. 2005;85:503–508.
    1. Ersser SJ, Cowdell FC, Latter SM, et al. Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support. Br J Dermatol. 2010;163:1044–1049.
    1. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272–284.
    1. Ersser SJ, Cowdell FC, Nicholls PG, et al. A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis. J Eur Acad Dermatol Venereol. 2012;26:738–745.
    1. Horne R, Weinman J, Barber N, et al. 2005. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). (last accessed: 27 September 2012)
    1. Armstrong AW, Watson AJ, Makredes M, et al. Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. Arch Dermatol. 2009;145:1230–1236.
    1. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12:98.
    1. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55:607–613.
    1. Gerdes S, Zahl VA, Weichenthal M, et al. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology. 2009;220:38–43.
    1. Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25:2429–2438.
    1. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6.
    1. Fleischer AB, Jr, Feldman SR, Rapp SR, et al. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol. 1996;107:26–29.
    1. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215:17–27.
    1. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol. 2006;126:1438–1440.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다